Kenvue Inc. $KVUE Shares Purchased by Alps Advisors Inc.

Alps Advisors Inc. boosted its position in Kenvue Inc. (NYSE:KVUE) by 5,815.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,472,224 shares of the company’s stock after buying an additional 1,447,336 shares during the quarter. Alps Advisors Inc.’s holdings in Kenvue were worth $25,396,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. lifted its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Kenvue in the 4th quarter worth $26,000. SBI Securities Co. Ltd. lifted its holdings in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares in the last quarter. Leonteq Securities AG acquired a new position in Kenvue in the 4th quarter worth $45,000. Finally, Hantz Financial Services Inc. lifted its holdings in Kenvue by 157.2% in the 3rd quarter. Hantz Financial Services Inc. now owns 2,850 shares of the company’s stock worth $46,000 after buying an additional 1,742 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE opened at $18.08 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $17.41 and its 200-day moving average is $17.53. The stock has a market cap of $34.70 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 1.37 and a beta of 0.54. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.24 earnings per share. On average, analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s payout ratio is currently 97.65%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KVUE shares. Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Citigroup cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $19.33.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.